Bumper Crop Of Consumer Health Deals Expected As Large Firms Prune Portfolios
This article was originally published in The Tan Sheet
A surge of M&A transactions in 2014 and early 2015 likely will result in brand spin-offs as big firms focus on core elements of their portfolios, consumer health market experts say. Fragmentation in the market, low interest rates and participation by private equity will drive more, though likely smaller deals.
You may also be interested in...
P&G could divest, at one fell swoop, prestige fragrances, makeup brands Cover Girl and Max Factor, and salon and small retail hair-care brands, analysts speculate, following reports that the firm is exploring a possible sale or IPO of personal care and beauty brands en masse.
The private equity firm’s H.I.G. Growth Partners capital investment affiliate merges two of its businesses, Integrity Nutraceuticals and Cornerstone Research & Development, into Capstone Nutrition. CEO Greg Horn says “we really occupy a niche” in “a pretty fragmented industry” with custom formulations for every product.
Consumer health products are grouped with vaccines and oncology drugs in Pfizer’s internal reorganization that takes effect in January 2014. Pfizer’s realignment into three organizations represents a step in the firm’s multi-year deliberation over whether to split its business.